Welcome to
Chiesi group
According to the official data published by the European Patent Office (EPO), also for 2021 Chiesi Group has been confirmed as the first Italian pharmaceutical company and ranks fourth among Italian companies across all sectors for filing the highest number of patents.
An important milestone made possible thanks Chiesi’s commitment to supporting the scientific progress needed to improve people’s lives around the world.
Through the efforts of more than 650 researchers working in the 8 Chiesi Research Centres in Italy (Parma), Germany, France, Sweden, United Kingdom, Canada, United States, China, and with an investment in R&D of €478.8 million, the Group continued to improve its innovation capacity.
Despite the ongoing pandemic, Italy achieved a record in the number of patent applications (+6.5%, far above the average European growth that has settled at +2.7%). After all, "the strong demand for patents last year shows that innovation has remained robust"[1], said EPO President António Campinos. "It highlights the creativity and resilience of innovators in Europe and worldwide. They have filed higher numbers of patent applications and the strong growth in digital technologies provides compelling evidence of the digital transformation taking place across all sectors and industries"[2], he said.
[1] https://www.epo.org/news-events/news/2022/20220405.html.
[2] Ibidem.
